<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04544917</url>
  </required_header>
  <id_info>
    <org_study_id>20190762</org_study_id>
    <nct_id>NCT04544917</nct_id>
  </id_info>
  <brief_title>SmartManage Stress Management for HIV+ Cancer Survivors</brief_title>
  <official_title>Development of an eHealth-based Cognitive Behavioral Stress and Self-Management Intervention to Reduce Symptom Burden in HIV+ Gay and Bisexual Men Who Have Sex With Men (MSM) Treated for Non-Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Cancer Society, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to design and refine a web-based platform developed for managing&#xD;
      symptom burden in men who have sex who are HIV+ cancer survivors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of eligible SMM that agree to participate</measure>
    <time_frame>Up to one year</time_frame>
    <description>Feasibility of the intervention will be reported as the proportion of eligible sexual minority men (SMM) who agree to participate versus decline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>USE Questionnaire Scores</measure>
    <time_frame>Week 10</time_frame>
    <description>Acceptability of the intervention will be reported as Usefulness, Satisfaction and Ease of Use (USE) Questionnaire Scores. USE is a 30-item questionnaire with a total score ranging from 30-240 with the higher score indicating greater acceptability of the intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cancer</condition>
  <condition>Hiv</condition>
  <condition>Stress</condition>
  <arm_group>
    <arm_group_label>SmartManage Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive ten 90-minute weekly therapist delivered SmartManage group sessions via video conference. Participants will have access to the SmartManage web platform, which will also guide the live intervention sessions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Educational Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group will view ten weekly control content video recorded sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>SmartManage for HIV+ cancer survivors</intervention_name>
    <description>Ten weekly therapist delivered group sessions delivered via web conference. Sessions focus on cognitive behavioral stress management, psychoeducation, and management strategies for dual diagnosis of HIV and cancer. Participants will have access to the SmartManage web platform which has all intervention material, resources, and exercises.</description>
    <arm_group_label>SmartManage Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Educational Control</intervention_name>
    <description>Participants in the control condition will view ten videos over ten weeks, consisting of informational and educational material relevant to cancer and HIV.</description>
    <arm_group_label>Educational Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18 years or older&#xD;
&#xD;
          2. Fluent in English&#xD;
&#xD;
          3. Have evidence of at least one form of non-metastatic solid tumor cancer or blood&#xD;
             cancer&#xD;
&#xD;
          4. Be at least 30 days post active primary cancer treatment&#xD;
&#xD;
          5. Self identify as a sexual minority cisgender man&#xD;
&#xD;
          6. Self-report having been diagnosed with HIV&#xD;
&#xD;
          7. Have reliable access to a computer/device with internet accessibility&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have had one of the following exclusionary cancer types: Non-melanoma skin cancer,&#xD;
             brain cancer, eye cancer, history of some form of pediatric cancer (if that is&#xD;
             participant's only cancer diagnosis)&#xD;
&#xD;
          2. History of advanced (metastatic) cancer of any type&#xD;
&#xD;
          3. Inpatient treatment for severe mental illness in the past 12 months and/or suicidality&#xD;
             of moderate or greater risk&#xD;
&#xD;
          4. Appears actively intoxicated or otherwise unable to provide full informed consent&#xD;
&#xD;
          5. Have any other medical condition resulting in predicted live expectancy of less than&#xD;
             12 months&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male sex assigned at birth and self-identify as male.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank J Penedo, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc J Puccinelli, Ph.D.</last_name>
    <phone>3052433508</phone>
    <email>mpuccinelli@miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Madeline Krause, MSEd</last_name>
    <phone>3052433329</phone>
    <email>madeline@miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc J Puccinelli, PhD.</last_name>
      <phone>305-243-3508</phone>
      <email>mpuccinelli@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Frank Penedo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Frank Penedo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Symptom burden</keyword>
  <keyword>Cognitive behavioral stress management</keyword>
  <keyword>Intervention development</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

